

THE PRESENT AND FUTURE

JACC STATE-OF-THE-ART REVIEW

The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation

JACC State-of-the-Art Review



A. John Camm, MD,^a Gerald V. Naccarelli, MD,^b Suneet Mittal, MD,^c Harry J.G.M. Crijns, MD, PhD,^d Stefan H. Hohnloser, MD,^e Chang-Sheng Ma, MD,^f Andrea Natale, MD,^g Mintu P. Turakhia, MD, MAS,^h Paulus Kirchhof, MD, DS^{i,j,k,l}

ABSTRACT

The considerable mortality and morbidity associated with atrial fibrillation (AF) pose a substantial burden on patients and health care services. Although the management of AF historically focused on decreasing AF recurrence, it evolved over time in favor of rate control. Recently, more emphasis has been placed on reducing adverse cardiovascular outcomes using rhythm control, generally by using safe and effective rhythm-control therapies (typically antiarrhythmic drugs and/or AF ablation). Evidence increasingly supports early rhythm control in patients with AF that has not become long-standing, but current clinical practice and guidelines do not yet fully reflect this change. Early rhythm control may effectively reduce irreversible atrial remodeling and prevent AF-related deaths, heart failure, and strokes in high-risk patients. It has the potential to halt progression and potentially save patients from years of symptomatic AF; therefore, it should be offered more widely. (J Am Coll Cardiol 2022;79:1932-1948) © 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Atrial fibrillation (AF) is the most common sustained arrhythmia in adults, with approximately 44 million individuals estimated to have AF or atrial flutter worldwide.^{1,2} In addition, there are many patients with undiagnosed AF who often may be first detected after a stroke, development of left ventricular dysfunction, or incidentally.^{3,4} AF is associated with substantial mortality and morbidity, which pose a significant burden to patients and health care services.²

Management of the condition has evolved over time and there has been a therapeutic paradigm shift away from concentrating solely on prevention of AF recurrence towards ventricular rate control, based on so-called “rate versus rhythm control” randomized trials conducted >2 decades ago.⁵⁻⁸ With the more recent development of targeted therapies aimed specifically at restoration and maintenance of sinus rhythm with antiarrhythmic drugs (AADs) and left atrial ablation, it became



Listen to this manuscript's audio summary by Editor-in-Chief Dr Valentin Fuster on JACC.org.

From the ^aCardiovascular Clinical Academic Group, St George's University of London, London, United Kingdom; ^bPenn State Heart and Vascular Institute, Penn State University, Hershey, Pennsylvania, USA; ^cSnyder Center for Comprehensive Atrial Fibrillation and Department of Cardiology, Valley Health System, Ridgewood, New Jersey, USA; ^dDepartment of Cardiology, Maastricht University Medical Centre (MUMC) and Cardiovascular Research Institute (CARIM), Maastricht, the Netherlands; ^eDepartment of Cardiology, J.W. Goethe University, Frankfurt, Germany; ^fNational Clinical Research Center for Cardiovascular Diseases, Beijing, China; ^gTexas Cardiac Arrhythmia Institute, St David's Medical Center, Austin, Texas, USA; ^hCenter for Digital Health and Department of Medicine, Stanford University, Stanford, California, USA; ⁱDepartment of Cardiology, University Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ^jDZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Berlin, Germany; ^kAtrial Fibrillation Network (AFNET), Münster, Germany; and the ^lInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

Manuscript received November 19, 2021; revised manuscript received March 1, 2022, accepted March 4, 2022.

HIGHLIGHTS

- AF is the most common adult arrhythmia, associated with substantial patient and health care burden.
- Increasing evidence supports early rhythm control for most patients with recently diagnosed AF as well as for those who are symptomatic.
- A paradigm shift is evolving in favor of rhythm control rather than rate control for patients with new-onset AF.

necessary to re-assess their impact on major adverse cardiovascular outcomes, such as death, stroke, systemic embolism, or progression of heart failure, as well as AF recurrence and quality of life (QoL).^{9,10} Results from several subsequent trials and observational studies suggest that optimal rhythm management may be preferable to simple rate control.^{11,12}

In the last few years, early intervention with rhythm control in the form of AADs or catheter ablation has shown promising results in maintaining sinus rhythm, and may delay progression of paroxysmal AF to persistent or permanent AF.¹²⁻¹⁴ In this article the rationale and evidence for more widespread adoption of early rhythm control in AF management are explored.

CURRENT AF MANAGEMENT

Management comprises 3 main domains summarized in the “ABC” scheme of the 2020 European Society of Cardiology (ESC) atrial fibrillation guidelines; these are “A” for anticoagulation/avoid stroke, “B” for better symptom control using rate and rhythm management, and “C” for therapy of concomitant cardiovascular conditions.^{2,15,16}

AADs typically used for restoration and/or maintenance of sinus rhythm are amiodarone, dofetilide, dronedarone, flecainide, propafenone, and sotalol.² Pharmacological rate-control strategies aim to regulate ventricular rate during AF with atrioventricular nodal blocking agents, mainly beta-blockers, nondihydropyridine calcium-channel blockers, digoxin, and occasionally amiodarone.² Rarely, atrioventricular node ablation and permanent pacing may be considered.

The current use of rhythm-control therapy is based on evidence generated in key trials originally conducted to compare rhythm vs rate control strategies. These include the following studies: PIAF

(Pharmacological Intervention in Atrial Fibrillation), AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management), RACE (Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation), AF-CHF (Atrial Fibrillation and Congestive Heart Failure), STAF (Strategies of Treatment of Atrial Fibrillation), and J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) (Table 1).¹⁷⁻²² Overall, few

significant differences in important endpoints have been observed between rhythm- and rate-control strategies in these comparison trials (Table 2), but meta-analyses have shown that fewer hospitalizations were required to deliver simple rate control.¹⁸⁻²⁰

As a result, treatment currently defaults to initial rate control, with rhythm control being reserved to improve symptoms that persist despite adequate rate control.^{2,16} General AF registries suggest that 75%-85% of patients with AF are not treated with rhythm-control therapy.^{23,24}

Not surprisingly, sinus rhythm maintenance was higher in patients receiving rhythm-control therapy than in those receiving rate-control therapy.^{20,22} Although the findings from RACE suggest that maintenance of sinus rhythm is less important than concomitant cardiovascular disease in causing cardiovascular events, the ensuing RACE III trial did not find a strong effect of intensive therapy of concomitant cardiovascular conditions after cardioversion on recurrent AF or on outcomes.²⁵⁻²⁷ However, effective rhythm control may be beneficial for prevention of severe cardiovascular events in addition to being indicated in patients with prominent symptoms of AF.^{19,28}

After prespecified covariate adjustments for baseline characteristics in the AFFIRM trial, there was a trend towards a higher mortality for rhythm control compared with rate control.¹⁸ Similarly, in RACE, mortality tended to be lower with rate control compared with rhythm control, particularly in female patients or those with hypertension, although the overall patient number was small.^{19,29,30} Conversely, in a subgroup of patients with no heart failure at baseline in the AFFIRM trial, there was a significantly increased risk of incident heart failure and/or cardiac death in the rate-control arm compared with the rhythm-control arm.³¹ Predictors of mortality in AFFIRM were older age, comorbidities, and use of digoxin or AADs, whereas use of anticoagulation and sinus rhythm during follow-up were associated with lower mortality.³²

In the PIAF, AFFIRM, and STAF trials, fewer patients were hospitalized in the rate-control group

ABBREVIATIONS AND ACRONYMS

- AAD** = antiarrhythmic drugs
- AF** = atrial fibrillation
- ESC** = European Society of Cardiology
- RCT** = randomized clinical trials
- QoL** = quality of life

TABLE 1 Study Design of Trials Using Rhythm- and Rate-Control Strategies in Treatment of AF

Trial ^a	N	Follow-Up	AF Classification	Rhythm-Control Strategy ^b	Rate-Control Strategy	Anticoagulation
PIAF ¹⁷	252	1 y	Persistent AF	Amiodarone for 3 wks, cardioversion thereafter if needed. Amiodarone for maintenance. For recurrences, therapy as needed at physician's discretion.	Diltiazem. Additional therapy as needed at physician's discretion.	All patients
AFFIRM ¹⁸	4,060	Mean: 3.5 y; maximum: 6 y	Recurrent non-permanent AF	At physician's discretion: amiodarone (62.8% used at any time), disopyramide (4.3%), flecainide (8.3%), moricizine (1.7%), procainamide (8.5%), propafenone (14.5%), quinidine (7.4%), sotalol (41.4%) and combinations of these. Dofetilide could be used once available (0.6%).	At physician's discretion: beta-blockers, calcium-channel blockers (verapamil and diltiazem), digoxin, or combinations of these.	Continuous OAC encouraged in the rhythm-control group, but could be stopped at physician's discretion. ^c
RACE ¹⁹	522	Mean: 2.3 y	Persistent AF or AFL	Electrical cardioversion then AAD therapy with sotalol. Amiodarone, flecainide, and propafenone used for recurrences.	Digitalis, a nondihydropyridine calcium-channel blocker, or a beta-blocker, alone or in combination.	OAC for 4 wks before and 4 wks after cardioversion. OAC could be stopped at 1 mo. ^d
STAF ¹⁴⁷	200	36 mo	Persistent AF	Internal or external cardioversion, with repeated cardioversions for AF recurrence. For prophylaxis of AF recurrence: class I AADs or sotalol ^e , or beta-blocker and/or amiodarone. ^f	Beta-blockers, digitalis, calcium antagonists, or AV-nodal ablation/modification with/without a pacemaker.	All patients
AF-CHF ²⁰	1,376	Mean: 37 mo; maximum 74 mo	History of AF with ECG documentation ^g	Aggressive therapy with AADs and electrical cardioversion within 6 wks of randomization if sinus rhythm not attained. Repeat cardioversions for AF recurrence. Amiodarone for maintenance and sotalol or dofetilide if required. Amiodarone (82%), dofetilide (<1%), and sotalol (2%).	Adjusted doses of beta-blockers with digitalis. AV-nodal ablation with pacemaker recommended if target heart rate not met.	All patients
J-RHYTHM ²²	885	Mean: 578 d	Paroxysmal AF	AADs according to contemporaneous Japanese guidelines. ¹⁴⁸ Amiodarone (0.5%), aprindine (7.2%), bepridil (6.7%), cibenzoline (20.8%), disopyramide (8.8%), flecainide (8.1%), pilsicainide (32.5%), pirmenol (1.0%), and propafenone (11.7%).	Beta-blockers, calcium-channel blockers, or digitalis.	All patients ^h

^aTraditional rhythm vs rate trials. ^bPercentages of patients receiving AADs provided where available and when more than one drug was used in the study. ^cIf SR maintained for ≥4, and preferably 12, consecutive weeks with AAD therapy. ^dIf SR present at 1 month, OAC could be stopped or changed to aspirin. ^eIn the absence of coronary heart disease and in patients with normal LV function. ^fIn patients with coronary heart disease or impaired LV function. ^gDefined as 1 episode lasting for ≥6 h or requiring cardioversion within the previous 6 mo or an episode lasting for ≥10 min within the previous 6 mo and previous electrical cardioversion for AF. ^hAccording to a protocol modified from that used in AFFIRM.

AAD = antiarrhythmic drug; AF = atrial fibrillation; AF-CHF = Atrial Fibrillation and Congestive Heart Failure; AFFIRM = Atrial Fibrillation Follow-up Investigation of Rhythm Management; AFL = atrial flutter; AV = atrioventricular; ECG = electrocardiogram; J-RHYTHM = Japanese Rhythm Management Trial for Atrial Fibrillation; LV = left ventricular; OAC = oral anticoagulation; PIAF = Pharmacological Intervention in Atrial Fibrillation; RACE = Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation; SR = sinus rhythm; STAF = Strategies of Treatment of Atrial Fibrillation.

than in the rhythm-control group.^{17,18,21} Similarly, fewer patients randomized to rate-control therapy were hospitalized in AF-CHF, a finding that was significant during the first year of the study.²⁰ These differences are routinely observed in all these randomized controlled trials (RCTs), as hospitalizations are inherently more likely with rhythm than rate control; this is because of the necessary monitoring during drug dose titration and the high likelihood of re-admissions associated with AAD use such as adverse drug effects and the need for other rhythm-control interventions such as left atrial ablation and cardioversion. When treatment adjustments for rhythm control were excluded, hospitalization rates from the AFFIRM analyses were similar in both cohorts.³³

In general, rates of stroke, systemic embolism, and major bleeding did not differ between treatment

strategies although event-free survival (events comprised total mortality, symptomatic stroke, systemic embolism, major bleeding, heart failure, and physical/psychological disability) was significantly better for rhythm control than rate control ($P = 0.0128$) in the J-RHYTHM trial.^{19,22,34,35}

QoL is significantly impaired in patients with AF compared with that of the general population and control groups, including patients with coronary heart disease.³⁶⁻³⁸ Despite this, QoL is not always measured in rhythm- vs rate-control trials, and there have been methodological weaknesses such as small sample size, lack of a control group, short-term follow-up periods (<6 months) and use of generic, rather than AF-specific, tools to assess QoL. Furthermore, substudies evaluating QoL, even from the larger trials, may not be sufficiently powered to provide meaningful analyses.³⁷ Notwithstanding

TABLE 2 Key Outcomes of Trials Using Rhythm- and Rate-Control Strategies in Treatment of AF

Trial	Primary Endpoint	Primary Endpoint Result	Patients in SR
PIAF ¹⁷	Improvement in AF-related symptoms (palpitations, dyspnea, and dizziness)	No significant difference between treatment arms	Rhythm control: 56% at study end Rate control: 10% at study end
AFFIRM ¹⁸	Overall mortality	Rhythm control: 24% at 5-y follow-up Rate control: 21% at 5-y follow-up (NS across follow-up period)	Rhythm control: 62.6% at 5-y follow-up Rate control: 34.6% at 5-y follow-up
RACE ¹⁹	Composite of death from cardiovascular causes, heart failure, thromboembolic complications, bleeding, the need for a pacemaker, or severe AEs	Rhythm control: 22.6% at study end Rate control: 17.2% at study end (noninferior, approaching superior)	Rhythm control: 39% at study end Rate control: 10% at study end
STAF ¹⁴⁷	Composite of death, stroke or transient ischemic attack, systemic embolism or cardiopulmonary resuscitation	Rhythm control: 5.54%/y Rate control: 6.09%/year (NS)	Rhythm control: 38% at last follow-up Rate control: 9% at last follow-up
AF-CHF ²⁰	Death from cardiovascular causes	Rhythm control: 27% at study end Rate control: 25% at study end (NS)	Rhythm control: 73% at 4-y follow-up Rate control: 30% to 41% during follow-up ^b
J-RHYTHM ²²	Composite of total mortality, symptomatic cerebral infarction, systemic embolism, major bleeding, hospitalization for heart failure ^c and physical/psychological disability requiring strategy alteration	Rhythm control: 15.3% at study end Rate control: 22.0% at study end (HR: 0.664; P = 0.0128)	Rhythm control: 72.7% at 3 y Rate control: 43.9% at 3 y

^aRequiring intravenous administration of diuretics. ^bData reported are patients with AF (59% to 10%).
AE = adverse event; HR = hazard ratio; NS = nonsignificant; SR = sinus rhythm; other abbreviation as in Table 1.

these limitations, the prevailing finding of rhythm- vs rate-control trials, such as RACE and PIAF, is that QoL is observed to improve under both strategies, often with little difference between the two.^{39,40} However, the CABANA (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation) trial and the RECORD-AF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation) observational trial, as well as large real-world registries such as the ESC-EHRA EORP-AF (ESC-European Heart Rhythm Association EURObservational Research Programme AF General Long-Term Registry), have reported a potential QoL benefit of rhythm control vs rate control.⁴¹⁻⁴³ Furthermore, when rhythm control therapy is chosen, there are consistent data that AF ablation improves QoL more than AAD therapy, perhaps because of chronotropic incompetence and resulting impairment of effort tolerance due to AAD therapy.^{42,44,45} Overall, 2 key lessons have emerged from recent trials. First, even small degrees of AF burden can lead to impairment in QoL, but restoration of sinus rhythm can improve QoL.⁴⁶ Second, reductions in AF burden can meaningfully improve QoL and risk of events such as heart failure, even without total freedom from AF.^{42,47,48}

Based on the available evidence, a treatment pattern based on offering initial rate control to most patients has emerged, reserving rhythm control to


relatively few patients who remain highly symptomatic (Figure 1). In clinical practice and in AF guidelines published by the ESC, and the American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS), rhythm control is added to rate control specifically and primarily to improve symptoms, or in specific patient subgroups who may be expected to benefit from a rhythm-control strategy (Figure 2).^{2,15,16}

EVOLUTION OF RHYTHM-CONTROL METHODS

AAD THERAPY FOR RHYTHM CONTROL. Pharmacological therapy for AF evolved substantially, and AAD therapy became a foundation of AF clinical management.⁴⁹ Maintenance of sinus rhythm has itself been associated with reductions in death and cardiovascular events.^{21,32} In general, AADs approximately double the likelihood of maintaining sinus rhythm compared with no rhythm-control therapy.⁵⁰⁻⁵⁵ In RCTs, the proportion of patients remaining in sinus rhythm varies, but typically ranges from 36% to 83% for rhythm control and 10% to 61% for rate control.^{12,18-20,54,56}

However, despite the clear effects of rhythm-control therapy on maintaining sinus rhythm, RCTs, systematic reviews, and meta-analyses have largely reported no significant difference between rhythm- and rate-control strategies with respect to all-cause


FIGURE 1 Principles of Current Guidelines for Rate/Rhythm Control in AF Management



mortality, cardiovascular mortality, stroke, heart failure, and other cardiovascular complications.^{5-8,57} Some earlier meta-analyses found trends that favored rate control for reducing risk of death, stroke, and hospitalization.^{58,59} However, it is possible that results from these trials conducted in the 1980s and 1990s were affected by the lack of safe and effective therapies, small sample sizes, inclusion of patients with long-standing AF, variable endpoints, less stringent monitoring, inadequate and unbalanced therapies for underlying medical conditions and anticoagulation therapy, unexpected sepsis in the rate-control arm as in AF-CHF, and the use of inappropriately high or suboptimal AAD doses, potentially

reducing efficacy or inciting proarrhythmia.^{15,20,60,61} In the AFFIRM trial, the high level of patient crossover from rate to rhythm control due to uncontrolled symptoms or heart failure highlights the importance of these aspects in patient management that were not taken into account during the design of that trial.¹⁸ Furthermore, even the longest trials in AF of 5-6 years could be considered to be relatively short compared with the years of potential AF adversity faced by patients with long-standing AF. For example, observational results from Canada also showed little difference in mortality until 4 years post-treatment initiation for rhythm or rate control, after which, long-term results progressively favored

FIGURE 2 Guideline Recommendations for Rhythm Management in Patients With Nonpermanent AF



In addition to use primarily in symptomatic patients, rhythm control is also currently often reserved for use in specific patient subgroups who may be expected to benefit from a rhythm-control strategy. ^aAs perceived by the patient according to validated tools. Abbreviations as in **Figure 1**. Adapted from Hindricks et al.²

rhythm control, with mortality decreasing in the rhythm-control group after year 5.⁶²

Initial enthusiasm for AADs was dampened after their association with excess mortality in patients with prior myocardial infarction, impaired left ventricular function, and ventricular ectopy, likely attributable to their proarrhythmic or negative inotropic effects, in the CAST (Cardiac Arrhythmia Suppression Trial), CAST II, SWORD (Survival With Oral d-Sotalol in Patients With Left Ventricular Dysfunction After Myocardial Infarction), and ALIVE (Azimilide Post-Infarct Survival Evaluation) studies in the 1990s.⁶³⁻⁶⁶ However, this was followed by the evaluation of AADs for rhythm control in patients with AF and the development of more atrial-specific AADs in the early 21st century.⁵⁰⁻⁵⁴ Furthermore, there has been progress in AF ablation (pulmonary vein isolation), which has been shown to be more

effective than AADs in maintaining sinus rhythm, (especially for patients in whom AADs are ineffective) with a good safety record.^{67,68}

At the same time, the management of cardiovascular comorbidities underwent considerable change. Some of these changes have directly or indirectly reduced the likelihood of AF, changed the hemodynamic, thrombogenic and electrophysiologic context in which AF occurs, and potentially improved its management and the possible success and safety of rhythm-control therapies. The use of “upstream” therapies (such as mineralocorticoid receptor antagonists, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and sodium-glucose co-transporter-2 inhibitors) has also been shown to be associated with improved maintenance of sinus rhythm.^{26,69,70-77} Lifestyle adjustments such as weight loss, increased exercise, and the management

TABLE 3 Study Design and Outcomes of EAST-AFNET 4 and ATHENA Trials		
	Trial	
	EAST-AFNET 4 ¹²	ATHENA ^{11,104,105}
N	2,789	4,628
Follow-up	Median: 5.1 y	Mean: 21 mo; Maximum: 2.5 y
AF classification	Recent-onset AF (≤12 mo) and at risk for stroke ³	Paroxysmal or persistent AF or AFL and ≥1 further risk factor
Rhythm control strategy ^b	Early rhythm control: AADs or ablation, as well as cardioversion for persistent AF. AADs: 87.0%; initial therapy: amiodarone (19.6%), dronedarone (16.7%), flecainide (35.9%), propafenone (7.0%), other AAD (7.6%) Ablation 8.0% ^c	Dronedarone
Comparator arm	Usual care: rate control supplemented by rhythm control only in symptomatic patients on adequate rate-control therapy ^d	Placebo/standard care
Anticoagulation	Standard care ^d	Rates of OAC use were similar to those seen in community practice
Primary endpoint	Composite of death from cardiovascular causes, stroke, or hospitalization with worsening heart failure or acute coronary syndrome	First hospitalization due to cardiovascular causes or death from any cause
Primary endpoint result	Occurred less often with early rhythm control than usual care (HR: 0.79; <i>P</i> = 0.005)	Dronedarone: 31.9% Placebo: 39.4% (HR: 0.76; <i>P</i> < 0.001)
Patients in sinus rhythm	Early rhythm control: 82.1% at 2 y Usual care: 60.5% at 2 y	Dronedarone: 42.9% ^e Placebo: 29.2% ^f

^aAge >75 years, previous TIA/stroke, or ≥2 of the following criteria: age >65 y, female, heart failure, hypertension, diabetes mellitus, severe coronary artery disease, chronic kidney disease, or left ventricular hypertrophy. ^bPercentages of patients receiving AADs provided where available and when more than one drug was used in the study. ^cPercentages of patients receiving AADs or ablation do not add up to 100%, as not all randomized patients received therapy. ^dPer guidelines on management of AF.^{16,149,150} ^eProportion of patients who did not have AF/AFL recurrence during the ATHENA trial out of patients who had undergone prior ablation and were in SR at baseline.

ATHENA = A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death from any Cause in Patients with AF/atrial flutter; EAST-AFNET 4 = Early Treatment of Atrial Fibrillation for Stroke Prevention Trial; TIA = transient ischemic attack; other abbreviations as in Tables 1 and 2.


of sleep apnea may also lead to reduction in AF burden.² Altogether, these advances form an improved background for successful, contemporary rhythm management. Modern management comprises therapies developed in this new context and includes left atrial ablation and the AAD dronedarone.¹¹ Regarding dronedarone, studies have shown that this drug is effective in maintaining sinus rhythm in patients who have experienced AF.⁷⁸ Although it is less effective than amiodarone in terms of reducing AF recurrence, dronedarone is associated with a better safety profile and is thus supported as a first-line treatment option for rhythm management in various patient populations.^{2,79}

AF ABLATION FOR RHYTHM CONTROL. Since the late 20th century, there has been rapid development in ablation, evolving from an experimental procedure to an important treatment option for AF that is recommended in numerous guidelines.^{2,15,16,80} Although ablation is accompanied by upfront complications because of its complex interventional nature, which can result in collateral damage to nearby organs and structures, the complication rate has declined in recent years in experienced centers due to quality improvement initiatives and advancement in

techniques and technologies.^{81,82} Additionally, ablation is more effective than AADs for maintaining sinus rhythm, including when used as first-line treatment for rhythm control.^{13,80,83-85}

Early studies of ablation often showed superiority in achieving sinus rhythm compared with pharmacological therapy, although these studies frequently enrolled patients with symptomatic AF who had previously failed AAD therapy, creating a potential bias.^{45,86-92} When investigating the efficacy of ablation in rhythm-control-naïve patients, however, the RAAFT (Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillation Trial) and RAAFT-2 trials showed that AF recurrence occurred in significantly fewer patients in the ablation group than in the AAD group (13% vs 63%, respectively, and 55% vs 72%, respectively).^{93,94} The longer-term MANTRA-PAF (Medical Antiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation) study, which also included patients with symptomatic paroxysmal AF who had not received previous AAD therapy for AF, randomized patients to radiofrequency ablation or AAD therapy.⁸³ Although no significant difference in the cumulative AF burden (primary endpoint) was found between treatment arms across the 24-month

FIGURE 3 Rhythm Management in AF and Underlying Progression of Atrial Cardiomyopathy/Remodeling



Currently, rhythm control is recommended only after the development of refractory AF symptoms, which may be too late to prevent AF progression. Increasing evidence supports rhythm control as an important strategy in the early stages of AF in combination with rate control and upstream therapies, as outlined by the Atrial fibrillation Better Care (“ABC”) holistic pathway (A: anticoagulation/avoid stroke; B: better symptom management; C: cardiovascular and comorbidity optimization).² Importantly, management of lifestyle and comorbidities should begin well before AF manifestation in those at risk. Anticoagulation should be initiated as early as possible after AF onset and is sometimes initiated before AF onset when there is an underlying comorbidity requiring anticoagulation or short bursts of atrial tachyarrhythmia insufficient for formal diagnosis of AF at risk of stroke. AF-related symptoms which guidelines recommend to decide on therapy can occur at any stage after AF onset. Abbreviation as in [Figure 1](#).


trial period, the AF burden was lower for the ablation arm at the 24-month time point than for the AAD arm ($P = 0.007$). In addition, more patients in the ablation arm compared with the AAD-treated arm were free from any AF (85% and 71%, respectively; $P = 0.004$) and from symptomatic AF (93% and 84%, respectively; $P = 0.01$) at 24 months.⁸³ These observations were repeated at the 5-year follow-up, when the cumulative AF burden was lower for both groups vs baseline but significantly lower in the ablation than in the AAD group.⁶⁸

Results from the later CAPTAF (Catheter Ablation compared with Pharmacological Therapy for Atrial Fibrillation), CABANA, AATAC (Ablation vs Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device), and CASTLE-AF (Catheter Ablation vs Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial

Fibrillation) trials have shown that ablation can significantly reduce the burden of AF and frequency of AF recurrence compared with pharmacological rhythm-control treatment.^{44,47,87,93-95}

In CABANA, the primary composite endpoint of death, disabling stroke, serious bleeding, or cardiac arrest was not different between the ablation and pharmacological-therapy arms. Also, the proportion of patients who had persistent or long-standing AF was reduced from approximately 57% across both arms at the start of the trial to 16% in the ablation arm vs 26% in the pharmacological-therapy arm, showing that ablation can benefit patients with long-standing AF.⁶⁷ AF ablation was associated with lower AF recurrence rates than pharmacological therapy (37% vs 58%, respectively, at 1-year follow-up and 50% vs 69%, respectively, at 3-years follow-up), concordant with other ablation trials. However, 17.1% of patients required a repeat ablation procedure during

CENTRAL ILLUSTRATION Summary of the Evolution of Atrial Fibrillation Rhythm Management



Camm AJ, et al. *J Am Coll Cardiol.* 2022;79(19):1932-1948.

Early atrial fibrillation (AF) treatment strategies (Yesterday) focused on escalation from initial rate control to rhythm control for those patients with persistent AF symptoms, reserving ablation as a late-stage intervention. More recent guidelines (Today) recommend a combination of rhythm and rate-control strategies for symptomatic patients, should adequate control not be achieved with first-line rate-targeting therapies. Our recommended treatment paradigm (Tomorrow's rhythm management) places rhythm control in a more prominent position within the rhythm management of AF, as a first-line therapy in combination with atrioventricular nodal therapy (rate control) for the majority of patients, with ablation as an important early treatment approach.

post-blanking follow-up, showing that ablation should not be seen as a one-off curative treatment for AF.^{67,95,96} Thus, CABANA confirms that AF ablation prevents recurrent AF more effectively than AAD therapy in a population of patients with established AF and concomitant cardiovascular conditions.⁹⁶

Small early ablation studies in patients with heart failure showed not only efficacy in terms of restoration of sinus rhythm but also improvement of left ventricular ejection fraction, even in patients with previously good ventricular rate control, and ablation has generally been superior to antiarrhythmic drug therapy in these patients.^{97,98} In the multicenter AATAC study, patients with persistent AF and

coexistent heart failure were randomized to catheter ablation or amiodarone therapy. At 2 years of follow-up, catheter ablation was superior to pharmacological treatment in achieving freedom from AF, reduced unplanned cardiovascular hospitalization and mortality, and substantial improvement in left ventricular ejection fraction, 6-minute walk distance, and QoL.⁴⁷

In CASTLE-AF, patients with coexisting AF and heart failure were assigned to catheter ablation or pharmacological rate-control therapy, with the former found to be associated with a reduced AF burden and an improved left ventricular ejection fraction compared with pharmacological treatment.⁹⁹

Furthermore, the composite primary endpoint (death or hospitalization for worsening heart failure) occurred in significantly fewer patients in the ablation group than in the pharmacological therapy group ($P = 0.006$). However, some have expressed concerns regarding methodological problems of this trial, such as small number of endpoint events, exclusion of patients from the intention-to-treat analysis, and patients with missing follow-up data.¹⁰⁰ Improvement of left ventricular function after AF ablation appears to be consistent across several randomized trials.¹⁰¹

These studies, in addition to the more recent STOP-AF (A Clinical Study of the Arctic Front Cryoablation Balloon for the Treatment of Paroxysmal Atrial Fibrillation), EARLY-AF (Early Aggressive Invasive Intervention for Atrial Fibrillation) trial, and CRYO-First (Cryoballoon catheter ablation vs AADs as a first-line therapy for patients with paroxysmal atrial fibrillation) trials provide important evidence showing that AF ablation is as safe as AAD therapy, and more effective in maintaining sinus rhythm when used as first-line rhythm control therapy in symptomatic patients with AF.^{13,85,89} Support of ablation as an effective therapeutic option in AF has been consistently shown in meta-analyses of trials exploring the impact of ablation on a range of hard clinical outcomes beyond AF recurrence.^{102,103} Although individual trials included in these analyses were relatively small, together they showed a clear benefit of ablation compared with pharmacological intervention, with significant reductions in mortality, stroke, and hospitalization, particularly within the setting of congestive heart failure.

NEW EVIDENCE SUPPORTING EARLY RHYTHM MANAGEMENT

Although AAD development had been largely concerned with the eradication of AF, safety was also an important issue. When a drug was developed solely as an atrial antiarrhythmic, it became necessary to design an RCT to document safety and to establish potential efficacy with regard to major cardiovascular outcomes in patients with AF. The ATHENA (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedaron 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death from any Cause in Patients with AF/atrial flutter) trial was conducted in 2005-2006 and remains the largest RCT of antiarrhythmic therapy in AF to date. A primary outcome of death or cardiovascular hospitalization was evaluated in 4,628 patients receiving dronedaron or placebo, both in addition to

standard therapy including rate control (Table 3).¹¹ Patients included in the trial had paroxysmal or persistent AF or atrial flutter within 6 months before randomization and met ≥ 1 CHADS₂ risk factors, left ventricular ejection fraction $\leq 40\%$, or left atrial enlargement.¹¹ The majority of patients received oral anticoagulants (OACs) and rate-control therapy.^{11,104} Other AAD therapy was not permitted and AF ablation was rarely used, rendering the control arm in ATHENA a rate control arm.¹⁰⁵ Treatment with dronedaron reduced the risk of a primary outcome of hospitalization due to unexpected cardiovascular events or death from any cause compared with placebo.^{11,106} Furthermore, there was a notionally significant reduction in secondary outcomes with dronedaron compared with control, including cardiovascular death (secondary outcome) and stroke (post hoc analysis).^{11,104}

Although it was shown in ATHENA that potential rhythm control resulted in better cardiovascular outcomes than standard care relying on rate control, the trial also demonstrated that dronedaron was a safe therapy for the ATHENA population.¹¹ Observational data capturing routine care replicate a lower risk of hospitalization for cardiovascular events, a composite outcome of cardiovascular hospitalization/death from any cause, and a lower risk of ventricular proarrhythmia for patients receiving dronedaron compared with other AADs.^{107,108} These beneficial effects of dronedaron have also been seen in patients with AF and coronary heart disease, and in those who underwent AF ablation before enrollment in the trial.^{12,105,109} However, in hospitalized patients with new or unstable heart failure with a reduced ejection fraction, and in patients with high-risk permanent AF or flutter, dronedaron was associated with adverse outcomes.^{110,111}

CLINICAL BENEFIT OF EARLY RHYTHM MANAGEMENT.

Equally important to recognizing the benefit of rhythm-control strategies for a wide range of patients is understanding the importance of early adoption of this approach. Early rhythm-control treatment in patients who have experienced a first AF episode or have recent-onset or paroxysmal AF has shown very promising results over and above the benefits of rhythm control itself.^{13,67,84,112} It has been suggested that the self-perpetuating effect of AF through structural remodeling of the atria underlines the importance of treating AF early to potentially halt progression and aid in maintenance of sinus rhythm.¹¹³⁻¹¹⁵ As just several days or weeks of arrhythmia can cause such atrial changes, early restoration of sinus rhythm could possibly prevent

this potentially irreversible damage and reduce the risk of stroke that is increased even with short episodes of asymptomatic AF.^{115,116} Data from the ATHENA trial and observational data from RECORD-AF have shown a lower likelihood of progression to permanent AF using a rhythm-control vs rate-control strategy.^{56,117}

The EAST-AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial) study in patients with AF diagnosed within 12 months before randomization who were at risk of stroke (Table 3) has recently been published in support of early comprehensive AF treatment, altering the view on early rhythm control as a general treatment concept.¹² In the study, patients were randomized to usual guideline-recommended care (primarily rate control plus OACs with rhythm control added to control symptoms as per ESC and AHA/ACC/HRS guidelines) or guideline-recommended care plus early rhythm-control treatment, consisting typically of AAD therapy, or, to a lesser degree, ablation, initiated directly after randomization.^{2,15,16,118} The first primary outcome was a composite of death from cardiovascular causes, stroke (ischemic or hemorrhagic), or hospitalization with worsening heart failure or acute coronary syndrome, which was reduced by 21% in patients assigned to early rhythm control compared with usual care ($P = 0.005$).¹² Each component of the first primary outcome was numerically less common in patients randomized to early rhythm control compared with usual care whereas there was no difference in the second primary outcome of number of nights hospitalized per year between the strategies.¹² Furthermore, the primary safety outcome (death, stroke, or serious adverse events related to rhythm-control therapy) was not different between randomized groups. Compared with those assigned to usual care, the occurrence of stroke was reduced by approximately one-third and total mortality was 16% lower in patients randomized to early rhythm control.¹² Serious adverse effects related to rhythm control therapy were more common in patients receiving early rhythm-control treatment than usual care, but occurred infrequently, as also seen in the STOP-AF First and CABANA trials, where many of the adverse effects previously associated with AADs were not reported.^{12,42,84}

A recent subanalysis of the EAST-AFNET 4 trial in patients with heart failure (predominantly those with preserved ejection fraction) showed that the first primary outcome occurred less often in patients receiving early rhythm-control therapy vs usual care, with the primary safety endpoint occurring in 17.9%

of participants in the early rhythm-control therapy group compared with 21.6% in the usual care group.¹¹⁹ Furthermore, promising results were also seen in a subanalysis stratifying treatment effects in EAST-AFNET 4 according to symptomatic status.¹²⁰ These data showed a consistent beneficial effect of early rhythm control vs usual care, independent of whether the patient was symptomatic or asymptomatic. A treatment effect was observed against the primary outcome of 0.77 (95% CI: 0.57-1.03) in asymptomatic patients, 0.84 (95% CI: 0.66-1.09) in those with mild or moderate symptoms, and 0.68 (95% CI: 0.47-0.99) in those with severe symptoms (P for interaction = 0.743).¹²⁰

As found in the PIAF, AFFIRM and RACE studies, no difference was found in QoL scores for the 2 strategies in the EAST-AFNET 4 study.¹² This was expected as symptom-guided rhythm-control therapy was part of usual care as per AF guidelines at the time and per current AF guidelines.^{2,121} However, in contrast to AFFIRM and RACE, stroke occurred less frequently in the early rhythm-control group than in the rate-control group.¹² The use of amiodarone and dronedarone as AAD options in EAST-AFNET 4 and the availability of AF ablation in patients who failed AAD therapy may have contributed to this outcome given that they can be safely used in patients with structural heart disease.¹⁰ In AFFIRM and RACE, sotalol was commonly used, with amiodarone available in both trials, and flecainide and propafenone administered following AF recurrence in RACE.

As a reaction to the findings of EAST-AFNET 4, further analyses exploring the importance of prompt AF treatment initiation have been performed. In the AFFIRM trial, patients diagnosed with AF within 6 months of study enrollment showed no difference in survival, cardiovascular hospitalization, or ischemic stroke between rate and rhythm-control strategies, suggesting the importance of early initiation of treatment, regardless of strategy.¹²² In support of this, initiation of either therapy ≤ 1 year of diagnosis was associated with a lower risk of the primary composite outcome of death from cardiovascular causes, ischemic stroke, admission to hospital for heart failure, or acute myocardial infarction in a nationwide health care database analysis based in Korea, replicating the beneficial effects seen in the EAST-AFNET 4 trial.¹²³ Another analysis in patients from the ESC-EHRA EORP-AF registry meeting EAST-AFNET 4 eligibility criteria showed a similar effect, although the association did not fulfil rigorous statistical testing, potentially due to the relatively young age of the population and the relatively small number

of patients.⁴³ Confirmatory observations were made in Optum, a large American health care database and in the National databases of Korea and Taiwan.¹²³⁻¹²⁶ Importantly, these routine health data analyses confirmed the safety of early rhythm-control therapy.^{43,123,125,126}

Overall, the benefits of early rhythm control have been shown for both pharmacological therapy and ablation, which are both highly effective when used in recent-onset AF.^{80,104,113,116,127,128} Among pharmacological therapies, dronedarone has been the most extensively studied AAD in terms of rhythm control and adverse cardiovascular outcomes in non-permanent AF, particularly in the ATHENA trial.^{10,11} Post hoc analyses by AF duration in this trial suggested that the effect of dronedarone was more robust among patients with short (<3 months) and intermediate (≥ 3 months to <24 months) AF/atrial flutter history than those with longer (≥ 24 months) history.¹¹² However, dronedarone should not be used in patients with permanent AF, heart failure with reduced ejection fraction or patients with recent heart failure decompensation/hospitalization. In a recent meta-analysis, patients with a shorter (≤ 1 -year) vs longer (>1-year) diagnosis-to-ablation time were shown to have lower risk of AF recurrence.¹²⁹ Results from the ATTEST (Atrial Fibrillation Progression Trial) showed that early ablation as part of standard care was superior to AAD therapy alone in delaying progression from recurrent paroxysmal AF to persistent AF, with the effect apparent at 1 year of follow-up and maintained over 3 years.¹⁴ Similar robust benefits of ablation as a first-line therapy have been seen across a range of trials, and as a result of the recent STOP-AF First study investigating outcomes of cryoballoon ablation when used as initial therapy in patients with paroxysmal AF naïve to rhythm-control therapy, the technique has recently been approved as a first-line therapy for AF in the United States.^{13,83,84,85,89} Analyses from CASTLE-AF, CABANA, and other studies supported early ablation in patients with AF and heart failure to prevent progression, as greater improvements in clinical outcomes were observed for patients in lower functional classes of heart failure.¹³⁰ Further analyses are required to fully assess whether AF progression to more persistent forms can be prevented by early rhythm control, in addition to lowering the risk of adverse cardiovascular outcomes.

Although catheter left atrial ablation may be the single best therapy, resources do not allow it to be used for all comers. AAD therapy must be improved and catheter ablation must be simplified to improve the clinical value of rhythm control. Academia and

the pharmaceutical industry continue to search for more effective and safe AADs such as small-conductance calcium-activated potassium (SK) channel inhibitors, TWIK-related acid-sensitive potassium channel (TASK-1) inhibitors, slow sodium channel inhibition and multichannel inhibitors, and alternative ablation approaches such as pulsed field ablation or electroporation.¹³¹⁻¹³⁶ Improvements in surgical therapy are being increasingly explored for the more refractory cases.¹³⁷

In real-world clinical practice, prompt treatment initiation may be hindered by the often asymptomatic nature of early AF. However, informal screening programs and the advent of mobile health devices such as smartwatches have shown increased AF detection rates.¹³⁸ One systematic review identified that single time point screening in the general ambulatory population has the potential to identify 1 new treatable case of AF in every 83 people aged ≥ 65 years screened.¹³⁹ Furthermore, exploiting pulse data captured by wearable sensors such as increasingly ubiquitous smartwatches can facilitate highly scalable AF detection and, as a result of ongoing investigation in this area, several mobile health devices have recently received U.S. Food and Drug Administration clearance for clinical use in AF detection.^{138,140,141} This may lead to an explosion of early but often asymptomatic cases of AF. Their best management has yet to be fully explored, but their identification will afford an opportunity to tackle the disease at a very early stage and to develop schemes, such as those involving clinical scores or artificial intelligence to assess which form of rhythm management should be considered.^{142,143}

CONCLUSIONS

Encouraging results from recent trials support rhythm control as a potentially important strategy in the early stages of AF, which could be a major step towards minimizing the burden of AF for both individuals and for global health care services (Figure 3). As a result, there is a paradigm shift well underway (Central Illustration) towards offering early rhythm control to all patients with recently diagnosed AF, which is not yet reflected in current guidelines. Concomitant rate control may also be needed until (or unless) rhythm control is fully effective; rate control without concomitant rhythm-control therapy in patients refractory to rhythm control is better thought of and described as an end-stage strategy for rate-control management.

Evidence supports early intervention in all patients with AF that has not become long-standing, where it

may be effective in reducing irreversible structural atrial cardiomyopathy, unmanageable symptoms, and/or strokes in patients at risk. Rhythm control also continues to fulfil an important role in controlling symptoms in those with more advanced AF and may be preferable in younger patients and patients at risk of stroke. In patients with AF and heart failure, catheter ablation may be preferred to AADs due to challenges in optimizing pharmacological strategy in this population.²

Given its possible benefits, the attainment and maintenance of sinus rhythm is widely thought to be an important goal in AF treatment. The continued evolution of AF treatment will result in AADs with a better safety profile than previous AADs, and improved ablation therapy may not only reduce but also virtually eliminate AF recurrences, especially when delivered early in the course of the disease.^{2,144} A better understanding of the mechanisms initiating AF will also improve long-term success of rhythm control.

Based on available evidence from early RCTs and registries, the primary goals for rhythm control has previously been to reduce AF-related symptoms, including those revealed by exercise intolerance and post-cardioversion, and to improve QoL in patients with AF.² However, current practice is moving towards offering rhythm control, not only for persistent symptoms, but also to reduce the risk of adverse cardiovascular outcomes in patients with new-onset and recently-diagnosed AF.^{2,16,145,146} Early therapy for AF is not only a possibility but is becoming necessary as informal medical screening and lay detection of AF become increasingly common.

Given the opportunities to reduce AF burden and halt progression that rhythm-control therapy affords, rhythm control should be offered more widely to avoid condemning a patient to a potential for many years of symptomatic AF and obligatory anticoagulation.

ACKNOWLEDGMENTS Editorial assistance was provided by Louise Gildea, PhD, and Heather Shawcross, PhD, of Fishawack Communications Ltd, and was funded by Sanofi. The authors thank Wanda Stipek, PharmD, BCPS, (Sanofi) for coordination of the development, facilitating author discussions, and critical review of this manuscript; and Mattias

Wieloch, MD, PhD, (Sanofi) for critical review of this manuscript.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

This work was supported by Sanofi for editorial assistance with article preparation only. Dr Camm has received consulting fees from Allergan, Arca, Acesion, Incarda, Menarini, Milestone, Sanofi, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Pfizer, Boston Scientific, Abbott, Biotronik, Medtronic, and Johnson and Johnson; and has received institutional grants from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Pfizer/Bristol Myers Squibb. Dr Naccarelli has received consultant fees from ARCA, Sanofi, Janssen, GlaxoSmithKline, Omeicos, Milestone, and Acesion. Dr Mittal has received consultant fees from Abbott, Baylis Medical, Boston Scientific, Medtronic, Philips, and Sanofi. Dr Crijns has received consultant/advisor/speaker fees from Acesion, Incarda, Sanofi, Roche, Ksyos, Corsano Health, and DZHK; has received support for educational activities from Medtronic, Abbott, and Boston Scientific; and has been supported by ZonMw (grant number 104021005 - RACE 9). Dr Hohnloser has received consulting fees from Bayer Healthcare, Boehringer Ingelheim, Bristol Myers Squibb, Boston Scientific, Daiichi-Sankyo, Gilead, Johnson & Johnson, Medtronic, Pfizer, Sanofi, Servier, and Zoll; and has received lecture fees from Bayer Healthcare, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Pfizer, Sanofi, and Medtronic. Dr Ma has received honoraria from Bristol Myers Squibb, Pfizer, Johnson & Johnson, Boehringer Ingelheim, and Bayer for giving lectures; no personal fees received. Dr Natale has been a consultant for Abbott, Baylis, Biosense Webster, Boston Scientific, Biotronik, and Medtronic. Dr Turakhia has received personal fees from Medtronic Inc, Abbott, Biotronik, Sanofi, Pfizer, Bayer, Myokardia, Johnson and Johnson, Milestone Pharmaceuticals, InCarda Pharmaceuticals, 100Plus, AliveCor, Acutus Medical, and BrightInsight; has received grants from Bristol Myers Squibb, the American Heart Association, Apple, Bayer, and the U.S. Food and Drug Administration; and is an editor for *JAMA Cardiology*. Dr Kirchof has received research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), German Centre for Cardiovascular Research, and from several drug and device companies active in atrial fibrillation; has received honoraria from several such companies in the past, but not in the last 3 years; is listed on 2 patents held by the University of Birmingham (Atrial Fibrillation Therapy WO 2015140571 and Markers for Atrial Fibrillation WO 2016012783); and has been partially supported by European Union BigData@Heart (grant agreement EU IMI 116074), AFFECT-AF (grant agreement 847770), and MAESTRIA (grant agreement 965286), British Heart Foundation (PG/17/30/32961 and PG/20/22/35093; AA/18/2/34218), German Centre for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK), and Leducq Foundation.

ADDRESS FOR CORRESPONDENCE: Prof A. John Camm, St George's University of London, Cranmer Terrace, London, SW17 0RE, United Kingdom. E-mail: jcammm@sgul.ac.uk. Twitter: [@johnncamm](https://twitter.com/johnncamm).

REFERENCES

1. Andrade J, Khairy P, Dobromir D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation. *Circ Res*. 2014;114:1453-1468.
2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the

- European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. 2021;42(5):373-498. <https://doi.org/10.1093/eurheartj/ehaa612>
3. Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. *Stroke*. 2013;44:3357-3364.
4. Schnabel RB, Haeusler KG, Healey JS, et al. Searching for atrial fibrillation poststroke: a white paper of the AF-SCREEN International Collaboration. *Circulation*. 2019;140:1834-1850.
5. Ahn J, Kim HJ, Choe JC, et al. Treatment strategies for atrial fibrillation with left ventricular systolic dysfunction: meta-analysis. *Circ J*. 2018;82:1770-1777.
6. Caldeira D, David C, Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. *Arch Cardiovasc Dis*. 2012;105:226-238.
7. Depoorter L, Sels L, Deschodt M, Van Grootven B, Van der Linden L, Tournoy J. Clinical outcomes of rate vs rhythm control for atrial fibrillation in older people: a systematic review and meta-analysis. *Drugs Aging*. 2020;37:19-26.
8. Sethi NJ, Feinberg J, Nielsen EE, Safi S, Gluud C, Jakobsen JC. The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a systematic review with meta-analysis and trial sequential analysis. *PLoS One*. 2017;12:e0186856.
9. Endo A, Kohsaka S, Suzuki S, et al. Impact of drug alteration to maintain rhythm control in paroxysmal atrial fibrillation. Subanalysis from J-RHYTHM study. *Circ J*. 2010;74:870-875.
10. Heijman J, Hohnloser SH, Camm AJ. Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future. *EP Europace*. 2021;23:ii14-ii22.
11. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. *N Engl J Med*. 2009;360:668-678.
12. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. *N Engl J Med*. 2020;383:1305-1316.
13. Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. *N Engl J Med*. 2021;384(4):305-315.
14. Kuck KH, Lebedev DS, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). *Europace*. 2021;23:362-369.
15. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2014;64(21):e1-e76.
16. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2019;74(1):104-132.
17. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. *Lancet*. 2000;356:1789-1794.
18. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med*. 2002;347:1825-1833.
19. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. *N Engl J Med*. 2002;347:1834-1840.
20. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. *N Engl J Med*. 2008;358:2667-2677.
21. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. *J Am Coll Cardiol*. 2003;41:1690-1696.
22. Ogawa S, Yamashita T, Yamazaki T, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM study. *Circ J*. 2009;73:242-248.
23. Fosbol EL, Holmes DN, Piccini JP, et al. Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. *J Am Heart Assoc*. 2013;2:e000110.
24. Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the Prevention of Thromboembolic Events-European Registry in Atrial Fibrillation (PREFER in AF). *Europace*. 2014;16:6-14.
25. Rienstra M, Van Gelder IC, Hagens VE, Veeger NJ, Van Veldhuisen DJ, Crijns HJ. Mending the rhythm does not improve prognosis in patients with persistent atrial fibrillation: a subanalysis of the RACE study. *Eur Heart J*. 2006;27:357-364.
26. Rienstra M, Hobbelt AH, Alings M, et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. *Eur Heart J*. 2018;39:2987-2996.
27. Nguyen BO, Crijns H, Tijssen JGP, et al. Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial. *Europace*. Published online November 13, 2021. <https://doi.org/10.1093/europace/euab270>
28. Hagens VE, Crijns HJ, Van Veldhuisen DJ, et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RATE Control Versus Electrical Cardioversion (RACE) study. *Am Heart J*. 2005;149:1106-1111.
29. Rienstra M, Van Veldhuisen DJ, Hagens VE, et al. Gender-related differences in rhythm control treatment in persistent atrial fibrillation: data of the Rate Control Versus Electrical Cardioversion (RACE) study. *J Am Coll Cardiol*. 2005;46:1298-1306.
30. Rienstra M, Van Veldhuisen DJ, Crijns HJ, Van Gelder IC. Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study. *Eur Heart J*. 2007;28:741-751.
31. Slee A, Saksena S. Impact of initial heart failure emergence on clinical outcomes of atrial fibrillation patients in the AFFIRM trial. *Am Heart J*. 2020;220:1-11.
32. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. *Circulation*. 2004;109:1509-1513.
33. Wyse DG, Slee A, Epstein AE, et al. Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. *Heart Rhythm*. 2004;1:531-537.
34. Sherman DG, Kim SG, Boop BS, et al. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study. *Arch Intern Med*. 2005;165:1185-1191.
35. DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. *Am Heart J*. 2005;149:650-656.
36. Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. *J Am Coll Cardiol*. 2000;36:1303-1309.
37. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. *Am J Med*. 2006;119:448-e441-e419.
38. van den Berg MP, Hassink RJ, Tuinenburg AE, et al. Quality of life in patients with paroxysmal atrial fibrillation and its predictors: importance of the autonomic nervous system. *Eur Heart J*. 2001;22:247-253.
39. Hagens VE, Ranchar AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. *J Am Coll Cardiol*. 2004;43:241-247.
40. Grönefeld GC, Lilienthal J, Kuck KH, Hohnloser SH. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. *Eur Heart J*. 2003;24:1430-1436.
41. Ha AC, Breithardt G, Camm AJ, et al. Health-related quality of life in patients with atrial fibrillation treated with rhythm control versus rate control: insights from a prospective international registry (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation:

- RECORD-AF). *Circ Cardiovasc Qual Outcomes*. 2014;7:896-904.
42. Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. *JAMA*. 2019;321:1275-1285.
43. Proietti M, Vitolo M, Harrison SL, et al. Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF long-term general registry. *Clin Res Cardiol*. 2021;111(1):70-84. <https://doi.org/10.1007/s00392-021-01914-y>
44. Blomström-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. *JAMA*. 2019;321:1059-1068.
45. Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. *JAMA*. 2010;303:333-340.
46. Samuel M, Khairy P, Champagne J, et al. Association of atrial fibrillation burden with health-related quality of life after atrial fibrillation ablation: substudy of the Cryoballoon vs Contact-Force Atrial Fibrillation Ablation (CIRCA-DOSE) randomized clinical trial. *JAMA Cardiol*. 2021;6(11):1324-1328. <https://doi.org/10.1001/jamacardio.2021.3063>
47. Biase LD, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device. *Circulation*. 2016;133:1637-1644.
48. Gupta D, Vijgen J, Potter TD, et al. Quality of life and healthcare utilisation improvements after atrial fibrillation ablation. *Heart*. 2021;107:1296.
49. Geng M, Lin A, Nguyen TP. Revisiting antiarrhythmic drug therapy for atrial fibrillation: reviewing lessons learned and redefining therapeutic paradigms. *Front Pharmacol*. 2020;11:581837. <https://doi.org/10.3389/fphar.2020.581837>
50. Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. *Lancet*. 2012;380:238-246.
51. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. *N Engl J Med*. 2004;351:2384-2391.
52. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. *N Engl J Med*. 2000;342:913-920.
53. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. *N Engl J Med*. 2005;352:1861-1872.
54. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. *N Engl J Med*. 2000;342:913-920.
55. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. *Circulation*. 2012;125:381-389.
56. Camm AJ, Breithardt G, Crijns H, et al. Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation: RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). *J Am Coll Cardiol*. 2011;58:493-501.
57. de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. *Arch Intern Med*. 2005;165:258-262.
58. Testa L, Biondi-Zoccai GG, Dello Russo A, Bellocchi F, Andreotti F, Crea F. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis. *Eur Heart J*. 2005;26:2000-2006.
59. Kumana CR, Cheung BM, Cheung GT, Ovedal T, Pederson B, Lauder IJ. Rhythm vs rate control of atrial fibrillation meta-analysed by number needed to treat. *Br J Clin Pharmacol*. 2005;60:347-354.
60. Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. *Circulation*. 2004;109:1973-1980.
61. Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. *Cochrane Database Syst Rev*. 2019;9:Cd005049.
62. Ionescu-Iltu R, Abrahamowicz M, Jackevicius CA, et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. *Arch Intern Med*. 2012;172:997-1004.
63. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. *N Engl J Med*. 1991;324:781-788.
64. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. *N Engl J Med*. 1992;327:227-233.
65. Waldo AL, Camm AJ, deRuiter H, et al. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). *Am J Cardiol*. 1995;75:1023-1027.
66. Camm AJ, Karam R, Pratt CM. The Azimilide Post-Infarct Survival Evaluation (ALIVE) trial. *Am J Cardiol*. 1998;81:35d-39d.
67. Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: the CABANA randomized clinical trial. *JAMA*. 2019;321:1261-1274.
68. Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial. *Heart*. 2017;103:368-376.
69. Naccarelli GV, Filippone EJ, Foy A. Do mineralocorticoid receptor antagonists suppress atrial fibrillation/flutter? *J Am Coll Cardiol*. 2021;78(2):153-155.
70. Rahimi K, Emberson J, McGale P, et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. *BMJ*. 2011;342:d1250.
71. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. *J Am Coll Cardiol*. 2008;51:828-835.
72. Yang Q, Qi X, Li Y. The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials. *BMC Cardiovasc Disord*. 2014;14:99.
73. Chang SH, Wu LS, Chiou MJ, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. *Cardiovasc Diabetol*. 2014;13:123.
74. Zhang Z, Zhang X, Korantzopoulos P, et al. Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. *BMC Cardiovasc Disord*. 2017;17:96.
75. Alexandre J, Dolladille C, Douesnel L, et al. Effects of mineralocorticoid receptor antagonists on atrial fibrillation occurrence: a systematic review, meta-analysis, and meta-regression to identify modifying factors. *J Am Heart Assoc*. 2019;8:e013267.
76. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. *Europace*. 2011;13:308-328.
77. Li H-L, Lip GYH, Feng Q, et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. *Cardiovasc Diabetol*. 2021;20:100.
78. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedronarone for maintenance of sinus rhythm in atrial fibrillation or flutter. *N Engl J Med*. 2007;357:987-999.
79. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedronarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. *J Cardiovasc Electrophysiol*. 2010;21:597-605.
80. Calkins H, Reynolds MR, Spector P, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation. *Circ Arrhythm Electrophysiol*. 2009;2:349-361.
81. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. *Europace*. 2018;20:157-208.
82. Rehman KA, Wazni OM, Barakat AF, et al. Life-threatening complications of atrial fibrillation ablation. *J Am Coll Cardiol EP*. 2019;5(3):284-291.
83. Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as

- initial therapy in paroxysmal atrial fibrillation. *N Engl J Med.* 2012;367:1587-1595.
- 84.** Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. *N Engl J Med.* 2021;384(4):316-324. <https://doi.org/10.1056/NEJMoa2029554>
- 85.** Kuniss M, Pavlovic N, Velagic V, et al. Cryoballoon ablation vs antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. *Europace.* 2021;23:1033-1041.
- 86.** Forleo GB, Mantica M, De Luca L, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. *J Cardiovasc Electrophysiol.* 2009;20:22-28.
- 87.** Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. *Circulation.* 2008;118:2498-2505.
- 88.** Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. *N Engl J Med.* 2006;354:934-941.
- 89.** Packer DL, Kowal RC, Wheelan KR, et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. *J Am Coll Cardiol.* 2013;61:1713-1723.
- 90.** Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF study. *J Am Coll Cardiol.* 2006;48:2340-2347.
- 91.** Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multicentre, randomized, controlled study (Catheter Ablation for the Cure of Atrial Fibrillation study). *Eur Heart J.* 2006;27:216-221.
- 92.** Krittayaphong R, Raungrattanaamporn O, Bhuripanyo K, et al. A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation. *J Med Assoc Thai.* 2003;86(suppl 1):S8-S16.
- 93.** Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2): a randomized trial. *JAMA.* 2014;311:692-700.
- 94.** Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. *JAMA.* 2005;293:2634-2640.
- 95.** Poole JE, Bahnson TD, Monahan KH, et al. Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug therapy in the CABANA trial. *J Am Coll Cardiol.* 2020;75:3105-3118.
- 96.** Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure. *Circulation.* 2021;143:1377-1390.
- 97.** Turagam MK, Garg J, Whang W, et al. Catheter ablation of atrial fibrillation in patients with heart failure: a meta-analysis of randomized controlled trials. *Ann Intern Med.* 2019;170:41-50.
- 98.** Hsu LF, Jaïs P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. *N Engl J Med.* 2004;351:2373-2383.
- 99.** Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. *N Engl J Med.* 2018;378:417-427.
- 100.** Packer M, Kowey PR. Building castles in the sky. *Circulation.* 2018;138:751-753.
- 101.** Willems S, Meyer C, de Bono J, et al. Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation. *Eur Heart J.* 2019;40:3793-3799.
- 102.** Barra S, Baran J, Narayanan K, et al. Association of catheter ablation for atrial fibrillation with mortality and stroke: a systematic review and meta-analysis. *Int J Cardiol.* 2018;266:136-142.
- 103.** Saglietto A, De Ponti R, Di Biase L, et al. Impact of atrial fibrillation catheter ablation on mortality, stroke, and heart failure hospitalizations: a meta-analysis. *J Cardiovasc Electrophysiol.* 2020;31:1040-1047.
- 104.** Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. *Circulation.* 2009;120:1174-1180.
- 105.** Vamos M, Calkins H, Kowey PR, et al. Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: insights from the ATHENA study. *Clin Cardiol.* 2020;43:291-297.
- 106.** Torp-Pedersen C, Crijns HJGM, Gaudin C, et al. Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. *EP Europace.* 2011;13:1118-1126.
- 107.** Goehring EL, Bohn RL, Pezzullo J, et al. Outcomes associated with dronedarone use in patients with atrial fibrillation. *Am J Cardiol.* 2020;135:77-83.
- 108.** Friberg L. Ventricular arrhythmia and death among atrial fibrillation patients using antiarrhythmic drugs. *Am Heart J.* 2018;205:118-127.
- 109.** Pisters R, Hohnloser SH, Connolly SJ, et al. Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. *Europace.* 2014;16:174-181.
- 110.** Køber L, Torp-Pedersen C, McMurray JJV, et al. Increased mortality after dronedarone therapy for severe heart failure. *N Engl J Med.* 2008;358:2678-2687.
- 111.** Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. *N Engl J Med.* 2011;365:2268-2276.
- 112.** Blomström-Lundqvist C, Marrouche N, Connolly S, et al. Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study. *Clin Cardiol.* 2020;43:1469-1477.
- 113.** Cosio FG, Aliot E, Botto GL, et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. *Europace.* 2008;10:21-27.
- 114.** Schotten U, Verheule S, Kirchhoff P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. *Physiol Rev.* 2011;91:265-325.
- 115.** Nattel S, Guasch E, Savelieva I, et al. Early management of atrial fibrillation to prevent cardiovascular complications. *Eur Heart J.* 2014;35:1448-1456.
- 116.** Kirchhoff P. Can we improve outcomes in AF patients by early therapy? *BMC Med.* 2009;7:72.
- 117.** Page RL, Connolly SJ, Crijns HJ, et al. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). *Am J Cardiol.* 2011;107:1019-1022.
- 118.** Kirchhoff P, Breithardt G, Camm AJ, et al. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial Fibrillation for Stroke Prevention trial. *Am Heart J.* 2013;166:442-448.
- 119.** Rillig A, Magnussen C, Ozga AK, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. *Circulation.* 2021;144(11):845-858. <https://doi.org/10.1161/circulationaha.121.056323>
- 120.** Willems S, Borof K, Brandes A, et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. *Eur Heart J.* 2021;43(12):1219-1230. <https://doi.org/10.1093/eurheartj/ehab593>
- 121.** Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J.* 2012;33:2719-2747.
- 122.** Yang E, Tang O, Metkus T, et al. The role of timing in treatment of atrial fibrillation: an AFFIRM substudy. *Heart Rhythm.* 2021;18:674-681.
- 123.** Kim D, Yang PS, You SC, et al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. *BMJ.* 2021;373:n991.
- 124.** Dickow J, Van Houten HK, Sangaralingham LR, et al. Generalizability of the EAST-AFNET 4 trial: assessing outcomes of early rhythm-control therapy in patients with atrial fibrillation. *Eur Heart J.* 2021;42(suppl 1):ehab724.0441.
- 125.** Chao T, Chan YH, Lip GYH, Chen SA. Early rhythm-control therapy in patients with atrial fibrillation: a nationwide cohort study. *Eur Heart J.* 2021;42. ehab724.0587.
- 126.** Kim D, Yang PS, You SC, et al. Comparative effectiveness of early rhythm control versus rate control for cardiovascular outcomes in patients with atrial fibrillation. *J Am Heart Assoc.* 2021;10:e023055.

- 127.** Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. *Circulation*. 2008;117:1518-1525.
- 128.** Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. *N Engl J Med*. 1999;340:1849-1854.
- 129.** Chew DS, Black-Maier E, Loring Z, et al. Diagnosis-to-ablation time and recurrence of atrial fibrillation following catheter ablation: a systematic review and meta-analysis of observational studies. *Circ Arrhythm Electrophysiol*. 2020;13:e008128.
- 130.** Sohns C, Zintl K, Zhao Y, et al. Impact of left ventricular function and heart failure symptoms on outcomes post ablation of atrial fibrillation in heart failure: CASTLE-AF Trial. *Circ Arrhythm Electrophysiol*. 2020;13:e008461.
- 131.** Yan Y, Skarsfeldt MA, Diness JG, Bentzen BH. Small conductance calcium activated K(+) channel inhibitor decreases stretch induced vulnerability to atrial fibrillation. *Int J Cardiol Heart Vasc*. 2021;37:100898.
- 132.** Wiedmann F, Beyersdorf C, Zhou XB, et al. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. *Cardiovasc Res*. Published online May 24, 2021. <https://doi.org/10.1093/cvr/cvab177>
- 133.** Leelapatana P, Thongprayoon C, Prasitlumkum N, Vallabhajosyula S, Cheungpasitporn W, Chokesuwattanaskul R. Role of ranolazine in the prevention and treatment of atrial fibrillation in patients with left ventricular systolic dysfunction: a meta-analysis of randomized clinical trials. *Diseases*. 2021;9.
- 134.** Chen W, Gan L, Wang Y. Characteristics of hERG and hNav1.5 channel blockade by sulcardine sulfate, a novel anti-arrhythmic compound. *Eur J Pharmacol*. 2019;844:130-138.
- 135.** Reddy VY, Dukkipati SR, Neuzil P, et al. Pulsed field ablation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and PEFCAT II. *J Am Coll Cardiol EP*. 2021;7:614-627.
- 136.** McBride S, Avazzadeh S, Wheatley AM, et al. Ablation modalities for therapeutic intervention in arrhythmia-related cardiovascular disease: focus on electroporation. *J Clin Med*. 2021;10.
- 137.** Badhwar V. Robotic-assisted biatrial Cox-maze ablation for atrial fibrillation. *J Thorac Cardiovasc Surg*. Published online October 5, 2021. <https://doi.org/10.1016/j.jtcvs.2021.09.053>
- 138.** Ding EY, Marcus GM, McManus DD. Emerging technologies for identifying atrial fibrillation. *Circ Res*. 2020;127:128-142.
- 139.** Lowres N, Olivier J, Chao T-F, et al. Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. *PLoS Med*. 2019;16:e1002903.
- 140.** Tison GH, Sanchez JM, Ballinger B, et al. Passive detection of atrial fibrillation using a commercially available smartwatch. *JAMA Cardiol*. 2018;3:409-416.
- 141.** Dörr M, Nohturfft V, Brasier N, et al. The WATCH AF trial: SmartWATCHes for detection of atrial fibrillation. *J Am Coll Cardiol EP*. 2019;5:199-208.
- 142.** Kim RS, Simon S, Powers B, et al. Machine learning methodologies for prediction of rhythm-control strategy in patients diagnosed with atrial fibrillation: observational, retrospective, case-control study. *JMIR Med Inform*. 2021;9:e29225.
- 143.** Malavasi VL, Vitolo M, Colella J, et al. Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort. *Intern Emerg Med*. Published online December 2, 2021. <https://doi.org/10.1007/s11739-021-02890-x>
- 144.** Son YJ, Baek KH, Lee SJ, Seo EJ. Health-related quality of life and associated factors in patients with atrial fibrillation: an integrative literature review. *Int J Environ Res Public Health*. 2019;16.
- 145.** National Institute for Health and Care Excellence. Atrial fibrillation: Diagnosis and Management. 2021. Accessed January 10, 2022. <https://www.nice.org.uk/guidance/ng196>
- 146.** Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. *Heart Rhythm*. 2017;14:e445-e494.
- 147.** Carlsson J, Boos C. Confounding factors in rate versus rhythm control trials in patients with atrial fibrillation: lessons from the strategies of treatment of atrial fibrillation (STAF) pilot study. *Card Electrophysiol Rev*. 2003;7:122-126.
- 148.** The Japanese Guidelines for Atrial Fibrillation Management. [In Japanese. *Jpn Circ J*. 2001;65:931-979.
- 149.** Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). *Eur Heart J*. 2010;31:2369-2429.
- 150.** Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37:e1-e88.

KEY WORDS antiarrhythmic drugs, atrial fibrillation progression, catheter ablation, early intervention, new-onset atrial fibrillation, paroxysmal atrial fibrillation

